Literature DB >> 31413094

Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma.

Elisabet E Manasanch1, Jatin J Shah2, Hans C Lee3, Donna M Weber3, Sheeba K Thomas3, Behrang Amini4, Jasper Olsem3, Brandon Crumpton3, Ashley Morphey3, Zuzana Berkova3, Lei Feng5, Robert Z Orlowski3,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31413094      PMCID： PMC7193461          DOI： 10.3324/haematol.2019.225375

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

Authors:  Robert Z Orlowski; Thomas E Stinchcombe; Beverly S Mitchell; Thomas C Shea; Albert S Baldwin; Stephanie Stahl; Julian Adams; Dixie-Lee Esseltine; Peter J Elliott; Christine S Pien; Roberto Guerciolini; Jessica K Anderson; Natalie D Depcik-Smith; Rita Bhagat; Mary Jo Lehman; Steven C Novick; Owen A O'Connor; Steven L Soignet
Journal:  J Clin Oncol       Date:  2002-11-15       Impact factor: 44.544

2.  A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma.

Authors:  Ajai Chari; Hearn J Cho; Amishi Dhadwal; Gillian Morgan; Lisa La; Katarzyna Zarychta; Donna Catamero; Erika Florendo; Nadege Stevens; Daniel Verina; Elaine Chan; Violetta Leshchenko; Alessandro Laganà; Deepak Perumal; Anna Huo-Chang Mei; Kaity Tung; Jami Fukui; Sundar Jagannath; Samir Parekh
Journal:  Blood Adv       Date:  2017-08-21

3.  PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

Authors:  Paul G Richardson; Robert L Schlossman; Melissa Alsina; Donna M Weber; Steven E Coutre; Cristina Gasparetto; Sutapa Mukhopadhyay; Michael S Ondovik; Mahmudul Khan; Carole S Paley; Sagar Lonial
Journal:  Blood       Date:  2013-08-15       Impact factor: 22.113

Review 4.  Proteasome inhibitors in cancer therapy.

Authors:  Elisabet E Manasanch; Robert Z Orlowski
Journal:  Nat Rev Clin Oncol       Date:  2017-01-24       Impact factor: 66.675

5.  Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma.

Authors:  Jesus G Berdeja; Lowell L Hart; Joseph R Mace; Edward R Arrowsmith; James H Essell; Rami S Owera; John D Hainsworth; Ian W Flinn
Journal:  Haematologica       Date:  2015-02-20       Impact factor: 9.941

6.  A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Authors:  David S Siegel; Thomas Martin; Michael Wang; Ravi Vij; Andrzej J Jakubowiak; Sagar Lonial; Suzanne Trudel; Vishal Kukreti; Nizar Bahlis; Melissa Alsina; Asher Chanan-Khan; Francis Buadi; Frederic J Reu; George Somlo; Jeffrey Zonder; Kevin Song; A Keith Stewart; Edward Stadtmauer; Lori Kunkel; Sandra Wear; Alvin F Wong; Robert Z Orlowski; Sundar Jagannath
Journal:  Blood       Date:  2012-07-25       Impact factor: 22.113

7.  Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Authors:  Jesús F San-Miguel; Vânia T M Hungria; Sung-Soo Yoon; Meral Beksac; Meletios Athanasios Dimopoulos; Ashraf Elghandour; Wieslaw Wiktor Jedrzejczak; Andreas Günther; Thanyaphong Na Nakorn; Noppadol Siritanaratkul; Paolo Corradini; Suporn Chuncharunee; Je-Jung Lee; Robert L Schlossman; Tatiana Shelekhova; Kwee Yong; Daryl Tan; Tontanai Numbenjapon; Jamie D Cavenagh; Jian Hou; Richard LeBlanc; Hareth Nahi; Lugui Qiu; Hans Salwender; Stefano Pulini; Philippe Moreau; Krzysztof Warzocha; Darrell White; Joan Bladé; WenMing Chen; Javier de la Rubia; Peter Gimsing; Sagar Lonial; Jonathan L Kaufman; Enrique M Ocio; Ljupco Veskovski; Sang Kyun Sohn; Ming-Chung Wang; Jae Hoon Lee; Hermann Einsele; Monika Sopala; Claudia Corrado; Bourras-Rezki Bengoudifa; Florence Binlich; Paul G Richardson
Journal:  Lancet Oncol       Date:  2014-09-18       Impact factor: 41.316

Review 8.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Authors:  Shaji Kumar; Bruno Paiva; Kenneth C Anderson; Brian Durie; Ola Landgren; Philippe Moreau; Nikhil Munshi; Sagar Lonial; Joan Bladé; Maria-Victoria Mateos; Meletios Dimopoulos; Efstathios Kastritis; Mario Boccadoro; Robert Orlowski; Hartmut Goldschmidt; Andrew Spencer; Jian Hou; Wee Joo Chng; Saad Z Usmani; Elena Zamagni; Kazuyuki Shimizu; Sundar Jagannath; Hans E Johnsen; Evangelos Terpos; Anthony Reiman; Robert A Kyle; Pieter Sonneveld; Paul G Richardson; Philip McCarthy; Heinz Ludwig; Wenming Chen; Michele Cavo; Jean-Luc Harousseau; Suzanne Lentzsch; Jens Hillengass; Antonio Palumbo; Alberto Orfao; S Vincent Rajkumar; Jesus San Miguel; Herve Avet-Loiseau
Journal:  Lancet Oncol       Date:  2016-08       Impact factor: 41.316

9.  Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.

Authors:  Jonathan L Kaufman; Roberto Mina; Andrzej J Jakubowiak; Todd L Zimmerman; Jeffrey J Wolf; Colleen Lewis; Charise Gleason; Cathy Sharp; Thomas Martin; Leonard T Heffner; Ajay K Nooka; R Donald Harvey; Sagar Lonial
Journal:  Blood Cancer J       Date:  2019-01-04       Impact factor: 11.037
  9 in total
  1 in total

1.  A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort.

Authors:  Jesus G Berdeja; Tara K Gregory; Edward A Faber; Lowell L Hart; Joseph R Mace; Edward R Arrowsmith; Ian W Flinn; Jeffrey V Matous
Journal:  Am J Hematol       Date:  2021-01-28       Impact factor: 10.047
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.